SeekingAlpha.com (Free subscription) | yesterday
The Burrill Report submits: Pharmaceutical giant Eli Lilly ( LLY ) opened a new state-of-the-art biotechnology center in San Diego, part of an ongoing effort by the drugmaker to transform itself into a biotech titan. The move follows a relocation of its ImClone headquarters to a new biopharmaceutical research cluster in New York and construction of its biotechnology research and development complex...
EconoSpeak (Free subscription) | 07/11/2009
In 1989, Joseph Wesbecker shot dead eight people and injured 12 others before killing himself at his place of work in Kentucky. Wesbecker had been taking the selective serotonin reuptake inhibitor (SSRI) antidepressant fluoxetine for four weeks before these homicides, and this led to a legal action against the makers of fluoxetine, Eli Lilly [1]. The case was tried and settled in 1994, and as part...
The best online pharmacy (Free subscription) | 06/11/2009
The FDA has approved Cymbalta (duloxetine HCl) for use in adult patients for the management of fibromyalgia. Cymbalta is marketed by Eli Lilly and previously was approved for use in patients with... you liked this article?
The best online pharmacy (Free subscription) | 06/11/2009
Cymbalta, a brand name from Eli Lilly for a drug called duloxetine, is in a class of drugs known as dual uptake inhibitors. Cymbalta medically formulated as Duloxetine Hydrochloride is a new... you liked this article?
Runesmith's Canadian Content (Free subscription) | 06/11/2009
I saw something rather disturbing this evening: an ad talking about erectile dysfunction. Hardly an uncommon sight in itself - except this one was on a Canadian station. I believe it was CTV NewsChannel. Unlike those endless, annoying American drug ads, this one didn't mention any specific drug - just informed the viewer that (apparently) 40% of men over 40 suffer from E.D. and referred them to a website:...
PharmaGossip (Free subscription) | 06/11/2009
Shane Ellison has a masters degree in organic chemistry and is a two-time recipient of the prestigious Howard Hughes Medical Institute Research Grant for his studies in biochemistry and physiology. Here Shane exposes the inner workings of the psycho/pharmaceutical industry, the manufacture and marketing of psychiatric drugs and the fact that the psycho/pharma industry is well aware their drugs do...
ReadWriteWeb (Free subscription) | 04/11/2009
Is Enterprise 2.0 a crock? Where are the use cases? Seven enterprise managers spoke about five principles that are emerging around this topic at the Enterprise 2.0 conference today in San Francisco. Sponsor Moderated by David Berlind , the group, all members of the 2.0 Adoption Council , looked at five issues to answer the question. Topics addressed: Workforce Transformation Business Process Optimization...
bioethics.com (Free subscription) | 04/11/2009
In the first half of this year, the drug giant Eli Lilly paid 3,971 doctors and other medical professionals an average of about $11,230 each. The payments were for participating in an average of 12 speaking or consulting engagements during those six months, according to a company spokeswoman. (New York Times)
CloudAve (Free subscription) | 04/11/2009
This is the one in answer to a recent post by provocateur Dennis Howlett in which Howlett asked whether Enterprise 2.0 is in fact a crock. Moderated by David Berlind from TechWeb he had a bevvy of Enterprise 2.0 practitioners. Therein lies the Big Lie. Enterprise 2.0 pre-supposes that you can upend hierarchies for the benefit of all. Yet none of that thinking has a credible use case you can generalize...
Fiercebiotech (Free subscription) | 04/11/2009
Eli Lilly's head of strategy, Gino Santini, was talking up the pharma giant's drug development strategy at the BIO-Europe confab in Vienna, outlining plans to boost its pace of licensing deals and beefing up the early-stage work in its early-stage research arm dubbed Chorus. Santini also said that Lilly is more interested in finding new financing to bankroll more expensive late-stage programs rather...
Communication and Culture Online (Free subscription) | 02/11/2009
IN THIS ISSUE: * RESUME SUBMISSION DEADLINES * FEATURED JOB AND INTERNSHIP POSTINGS * OPEN SOURCE CENTER (OSC) INFORMATION SESSION * WEST EUROPEAN CAREERS NIGHT * CREATIVE INDUSTRIES NETWORKING NIGHT * ELI LILLY & COMPANY INFORMATION SESSION * INTERVIEWING 101 * STARCOM INFORMATION SESSION * RESUME WRITING 101 * * * * * * * * * * * * * * * * * * * * * * * * RESUME SUBMISSION DEADLINES: 10/30/09:...
Fool.com (Free subscription) | 02/11/2009
Make sure you're holding the right stocks.
PharmaGossip (Free subscription) | 01/11/2009
By Martha Rosenberg ( about the author ) Page 1 of 2 page(s) opednews.com Permalink For OpEdNews: Martha Rosenberg - Writer Raise your hand if you've breathed a sign of relief seeing your doctor had a CME certificate next to the medical school diploma on the wall. Did your doctor pass , Bipolar Disorder: Individualizing Treatment to Improve Patient Outcomes, Part 2 "taught" by Trisha Suppes,...
Vox Verax (Free subscription) | 31/10/2009
Zachary Roth | October 29, 2009 TPM Muckraker Yesterday, Sen. Evan Bayh joined his colleague Joe Lieberman in suggesting that he may oppose health-care reform, citing concerns about the deficit. Bayh has long been one of the more conservative members of the Democratic caucus. But is his stance also affected by the fact that his wife has reportedly earned at least $2 million over the last six years...
Xconomy (Free subscription) | 31/10/2009
San Diego-based Amylin Pharmaceuticals (NASDAQ: AMLN) and its partner Eli Lilly got some positive news late Friday from the FDA. The agency now says the companies have clearance to market exenatide (Byetta) as a standalone therapy for diabetes, which means doctors won’t need to combine it with other common drugs, or hold it in reserve [...]
Videos